Norepinephrine transporter gene (NET) variants in patients with panic disorder

Neuroscience Letters

Volumn 333, Issue 1, 2002, Pages 41-44

  Sand, P G ^a   Mori, T ^b   Godau, C ^a   Stober G ^c   Flachenecker, P ^c   Franke, P ^d   Nothen M M ^e   Fritze, J ^a   Maier, W ^a   Lesch, K P ^a   Riederer, P ^a   Beckmann, H ^a   Deckert, J ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b NAGASAKI UNIVERSITY   (Japan)

^c UNIVERSITY OF BONN   (Germany)

^d GOETHE UNIVERSITY   (Germany)

^e UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Agoraphobia; Catecholamines; Norepinephrine transporter; Panic disorder

Indexed keywords

GLYCINE; ISOLEUCINE; NORADRENALIN TRANSPORTER; SERINE; THREONINE; VALINE;

AGORAPHOBIA; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; PANIC; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS;

AMINO ACID SUBSTITUTION; FEMALE; GENE FREQUENCY; HUMANS; MALE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PANIC DISORDER; PATIENTS; SYMPORTERS; VARIATION (GENETICS);

EID: 0037111007     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(02)00984-9     Document Type: Article

References (32)

1. Blakely R.D. Physiological genomics of antidepressant targets: keeping the periphery in mind. J. Neurosci. 21:2001;8319-8323.
2. Braune S., Albus M., Frohler M., Hohn T., Scheibe G. Psychophysiological and biochemical changes in patients with panic attacks in a defined situational arousal. Eur. Arch. Psychiatry Clin. Neurosci. 244:1994;86-92.
3. Bremner J.D., Krystal J.H., Southwick S.M., Charney D.S. Noradrenergic mechanisms in stress and anxiety: II, clinical studies. Synapse. 23:1996;39-51.
4. Butler J., O'Halloran A., Leonard B.E. The Galway Study of Panic Disorder II: changes in some peripheral markers of noradrenergic and serotonergic function in DSM III-R panic disorder. J. Affect Disord. 26:1992;89-99.
5. Carson R.P., Robertson D. Genetic manipulation of noradrenergic neurons. J. Pharmacol. Exp. Ther. 301:2002;410-417.
6. Charney D.S., Heninger G.R., Breier A. Noradrenergic function in panic anxiety; effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch. Gen. Psychiatry. 41:1984;751-763.
7. Coryell W., Noyes R., Clancy J. Excess mortality in panic disorder; a comparison with primary unipolar depression. Arch. Gen. Psychiatry. 39:1982;701-703.
8. Dupont W.D., Plummer W.D. Jr. Power and sample size calculations for studies involving linear regression. Control. Clin. Trials. 19:1998;589-601.
9. Eisenhofer G. The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol. Ther. 91:2001;35-62.
10. Gelernter J., Kruger S., Pakstis A.J., Pacholczyk T., Sparkes R.S., Kidd K.K., Amara S. Assignment of the norepinephrine transporter protein (NET1) locus to chromosome 16. Genomics. 18:1993;690-692.
11. Goldstein R.B., Weissman M.M., Adams P.B., Horwath E., Lish J.D., Charney D., Woods S.W., Sobin C., Wickramaratne P.J. Psychiatric disorders in relatives of probands with panic disorder and/or major depression. Arch. Gen. Psychiatry. 51:1994;383-394.
12. Gurguis G.N., Vitton B.J., Uhde T.W. Behavioral, sympathetic and adrenocortical responses to yohimbine in panic disorder patients and normal controls. Psychiatry Res. 71:1997;27-39.
13. Halushka M.K., Fan J.B., Bentley K., Hsie L., Shen N., Weder A., Cooper R., Lipshutz R., Chakravarti A. Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat. Genet. 22:1999;239-247.
14. Kendler K.S., Neale M.C., Kessler R.C., Heath A.C., Eaves L.J. Panic disorder in women: a population-based twin study. Psychol. Med. 23:1993;397-406.
15. Klerman G.L., Weissman M.M., Ouellette R., Johnson J., Greenwald S. Panic attacks in the community, social morbidity and health care utilization. J. Am. Med. Assoc. 265:1991;742-746.
16. Ko G.N., Elsworth J.D., Roth R.H., Rifkin B.G., Leigh H., Redmond D.E. Jr. Panic-induced elevation of plasma MHPG levels in phobic-anxious patients; effects of clonidine and imipramine. Arch. Gen. Psychiatry. 40:1983;425-430.
17. Mutchler K., Crowe R.R., Noyes R. Jr, Wesner R.W. Exclusion of the tyrosine hydroxylase gene in 14 panic disorder pedigrees. Am. J. Psychiatry. 147:(10):1990;1367-1369.
18. Nesse R.M., Cameron O.G., Buda A.J., McCann D.S., Curtis G.C., Huber-Smith M.J. Urinary catecholamines and mitral valve prolapse in panic-anxiety patients. Psychiatry Res. 14:1985;67-75.
19. Ohara K., Suzuki Y., Ochiai M., Terada H. Polymorphism in the promoter region of the alpha(2A)-adrenergic receptor gene and panic disorders. Psychiatry Res. 93:2000;79-82.
20. Owen D., Du L., Bakish D., Lapierre Y.D., Hrdina P.D. Norepinephrine transporter gene polymorphism is not associated with susceptibility to major depression. Psychiatry Res. 87:1999;1-5.
21. Rohde K., Fuerst R. Haplotyping and estimation of haplotype frequencies for closely linked biallelic multilocus genetic phenotypes including nuclear family information. Hum. Mutat. 17:2001;289-295.
22. Runkel F., Brüss M., Nöthen M.M., Stöber G., Propping P., Bönisch H. Pharmacological properties of naturally occurring variants of the human norepinephrine transporter. Pharmacogenetics. 10:2000;397-405.
23. Samochowiec J., Rybakowski F., Czerski P., Zakrzewska M., Stepien G., Pelka-Wysiecka J., Horodnicki J., Rybakowski J., K ., Hauser J. Polymorphisms in the dopamine, serotonin, and norepinephrine transporter genes and their relationship to temperamental dimensions measured by the temperament and character inventory in healthy volunteers. Neuropsychobiology. 43:2001;248-253.
24. Shannon J.R., Flattem N.L., Jordan J., Jacob G., Black B.K., Biaggioni I., Blakely R.D., Robertson D. Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N. Engl. J. Med. 342:2000;541-549.
25. Stöber G., Hebebrand J., Cichon S., Brüss M., Bönisch H., Lehmkuhl G., Poustka F., Schmidt M., Remschmidt H., Propping P., Nöthen M.M. Tourette syndrome and the norepinephrine transporter gene: results of a systematic mutation screening. Am. J. Med. Genet. 88:1999;158-163.
26. Stöber G., Nöthen M.M., Porzgen P., Brüss M., Bönisch H., Knapp M., Beckmann H., Propping P. Systematic search for variation in the human norepinephrine transporter gene: identification of five naturally occurring missense mutations and study of association with major psychiatric disorders. Am. J. Med. Genet. 67:1996;523-532.
27. Uhde T.W., Siever L.J., Post R.M., Jimerson D.C., Boulenger J.P., Buchsbaum M.S. The relationship of plasma free MHPG to anxiety and psycho-physical pain in normal volunteers. Psychopharmacol. Bull. 18:1982;129-132.
28. Versiani M., Cassano G., Perugi G., Benedetti A., Mastalli L., Nardi A., Savino M. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J. Clin. Psychiatry. 63:2002;31-37.
29. Wang Z.W., Crowe R.R., Noyes R. Jr. Adrenergic receptor genes as candidate genes for panic disorder: a linkage study. Am. J. Psychiatry. 149:1992;470-474.
30. Xu F., Gainetdinov R.R., Wetsel W.C., Jones S.R., Bohn L.M., Miller G.W., Wang Y., Caron M.G. Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. Nat. Neurosci. 3:2000;465-471.
31. Zaubler T.S., Katon W. Panic disorder in the general medical setting. J. Psychosom. Res. 44:1998;25-42.
32. Zill P., Engel R., Baghai T.C., Juckel G., Frodl T., Müller-Siecheneder F., Zwanzger P., Schüle C., Minov C., Behrens S., Rupprecht R., Heger U., Möller H.J., Bondy B. Identification of a naturally occurring polymorphism in the promoter region of the norepinephrine transporter and analysis in major depression. Neuropsychopharmacology. 26:2002;489-493.